Login  
 
            ANABOLIC STEROIDS       HGH & PEPTIDES       Ocandrolic/50mg       PROTECTION       SEX       SPECIAL OFFER       STEROIDS       WEIGHT LOSS      
 
HGH & PEPTIDES

100 x 1ml Insulin Syringes
ACTN3 100 mcg
ACVR2B (ACE-031)
ACVR2B
AICA ribonucleotide (AICAR)
Argreline Acetate 10mg
Aviva Systems Biology 13.3mg (40iu)
Aviva Systems Biology 26.6mg (80 IU)
CJC-1293 Modified GRF (1-29) 2mg
CJC-1295 DAC 2mg
CJC-1295 NO-DAC(MOD GRF 1-29)
Eprex(Erythropoietin)1000 IU/0,5 ml (8,4 mcg) x 6(Cilag AG International)
Eprex(Erythropoietin)10000 IU/1,0 ml (84 mcg) x 6(Cilag AG International)
Eprex(Erythropoietin)2000 IU/0,5 ml (16,8 mcg) x 6(Cilag AG International)
Eprex(Erythropoietin)3000 IU/0,3 ml (25,2 mcg) x 6(Cilag AG International)
Eprex(Erythropoietin)4000 IU/0,4 ml (33,6 mcg) x 6(Cilag AG International)
Eprex(Erythropoietin)40000 IU/1,0 ml (336 mcg) x 1(Cilag AG International)
Eprex(Erythropoietin)5000 IU/0,5 ml (42 mcg) x 6(Cilag AG International)
Eprex(Erythropoietin)6000 IU/0,6 ml (50,4 mcg) x 6(Cilag AG International)
Eprex(Erythropoietin)8000 IU/0,8 ml (67,2 mcg) x 6(Cilag AG International)
Fat Targeted Proapoptotic Peptide - CKGGRAKDC-GG-D(KLAKLAK)2 - 5mg
Follistatin 344 1mg
Fragment 176-191
GENOTROPIN(Somatropin) pre-filled pen GoQuick 12 mg(36IU) pen Phizer USA
Genotropin(Somatropine)16iu(5.3 mg)(Phizer USA)
GHRP – 2
GnRH (Triptorelin)
GnRH (Triptorelin)
Hexarelin(HEX)2mg
HGH PRO (Profound Product) 72IU 24mg
HGH ProClick Cartridge 90 IU - 30 mg Somatropin Profound
HGH ProClick Pen 30mg (90 IU) Profound SUMMER SALE!!!
Humalog(Insulin human, rDNA)100 IU/ml - 3 ml x 5 (Eli Lilly USA)
Human Growth Hormone(Somatropine) 100iu(10vial x 10iu)(Europe Pharmaceuticals)
Humatrope Lilly France 72 IU (24 mg) Somatropin
Hygetropin 200IU (25 Vials x 8 IU)
IGF-1 LR3 1mg
Ipamorelin 2mg
Melanotan II 10mg
MGF (IGF-1Ec) 2mg
Myostatin HMP(Human Myostatin Propeptide(GDF-8)98% 2mg
Norditropin(Somatropine)30IU(10mg/1.5mL)(Novo Nordisk Holland)
NovoRapid Penfill(Insulin aspart, rDNA)100 IU/ml - 3 ml x 5(Novo Nordisk Holland)
Orexin-A 5mg
PEG MGF 2mg
PT-141(Bremelanotide)10mg
Rastan Somatotropin 40UI(10x4IU) Pharmstandard
Riptropin 100IU HGH kit (10 x 10 IU) Blue top
Selank 5 mg
TB-500(Thymosin Beta 4)2mg
     ALL

Price: $ 79.00 
 
Quantity:




Ipamorelin 2mg

Item 12655

Ipamorelin: Potent New Peptide For Building More Muscle

Ipamorelin is a fascinating new muscle building discovery that is getting a lot of attention in the bodybuilding world. Like the GHRP-6 peptide (growth hormone releasing hexapeptide), it is a synthetic peptide that has powerful Growth Hormone releasing properties. And these GH releasing properties are what is of interest to athletes and bodybuilders since they can make a tremendous difference in the amount of muscle you can grow and how quickly you burn fat. Both Ipamorelin and GHRP-6 as well as numerous other peptides and research chemicals can be found at PurchasePeptides.com.

Whereas GHRP-6 is a hexapeptide, Ipamorelin is a penta-peptide. (Aib-His-D-2-Nal-D- Phe-Lys-NH2) And, the strength it displays may very well make regular old Growth Hormone (GH) obsolete. But what athletes and bodybuilders really want to know is what is this wonder peptide capable of doing, how is it used, and how does it compare to the other GHRP peptides?

Athletes are taking Ipamorelin in a 200mcg -300mcg dosage, two or three times daily, using a tiny insulin needle to inject. They usually start with the lower dose since side effects can include headaches or what feels like a head-rush. Ipamorelin can be taken at anytime but taking it about 30-45 minutes before a workout would seem ideal because of the pulse in Growth Hormone (GH) it creates allowing for maximum growth.

Studies on the effects of Ipamorelin on bone growth, body weight, and GH release showed some interesting conclusions.

In one experiment, various doses were administered over the course of 15 days to test the group's reactions.

There was a distinct and dose-dependent effect on body weight gain however, the treatment group did not show a change in total IGF-I levels. Nor did the treatment group produce serum markers of bone development. For example, the number of cells in the wide portion of the tibia (the shinbone) did not change significantly. This is a good thing because it suggests muscle growth with less potential for deformity of bone or cartilage.

The reaction of the pituitary to an aggressive i.v. dose of Ipamorelin showed that plasma GH levels were notably reduced whereas they were unchanged after a comparable dose of GHRH. This is actually a good thing as it suggests that Ipamorelin may not decrease your body's natural GH production - further demonstrating that Ipamorelin is a selective GH releaser.

Unlike GHRP-6, Ipamorelin does not induce hunger making it advantageous to those on a restricted calorie diet. And obviously, Ipamorelin's side-effects are enhanced when combined with anabolic steroids since they too influence Growth Hormone/Insulin Growth Factor release and production.

In another study in rats, Ipamorelin released GH from rat pituitary cells as effectively as GHRP-6.

Another document states that in healthy swine, Ipamorelin released GH with a consistency that is very comparable to GHRP-6. Also noteworthy was that none of the GH releasers tested affected FSH, LH, PRL or TSH blood serum plasma levels.

Ipamorelin in theory may increase Acetylchloine or Cortisol when used in higher dosages. However, and increase in Acetylchloine or Cortisol is even more likely with GHRP-2 and GHRP-6. In fact, in the case of Ipamorelin, there was little to no rise in Acetylcholine and Cortisol blood plasma levels even at injections more than 200 times higher than the effective dosage for comparable GH release.

This clearly proves that Ipamorelin is the first successful GHRP receptor agonist or chemical that binds to a receptor of a cell and triggers a response by that cell with a specific selectivity for the promotion of GH release by itself.

Another advantage to Ipamorelin is that it doesn't cause sudden spikes in prolactin or cortisol as does GHRP-2 and GHRP-6. Ipamorelin is slower in its delivery unlike GHRP's which spike GH levels at a more rapid rate. The slower release is more natural and has a more sustained effect.

All in all it looks as if Ipamorelin is the new wave in GH releasing peptides. It appear to be more potent, longer lasting and potentially safer to use in the long run. More studies are being conducted all the time but as it stands, Ipamorelin looks like a serious contender in the arsenal of anabolic advancement.

Ipamorelin, the first selective growth hormone secretagogue

  1. K Raun,
  2. BS Hansen,
  3. NL Johansen,
  4. H Thogersen,
  5. K Madsen,
  6. M Ankersen and
  7. PH Andersen
1.      Department of GH Biology, Novo Nordisk A/S, Malov, Denmark.

Abstract

The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (ECs) = 1.3+/-0.4nmol/l and Emax = 85+/-5% vs 2.2+/-0.3nmol/l and 100%). A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6 (ED50 = 80+/-42nmol/kg and Emax = 1545+/-250ng GH/ml vs 115+/-36nmol/kg and 1167+/-120ng GH/ml). In conscious swine, ipamorelin released GH with an ED50 = 2.3+/-0.03 nmol/kg and an Emax = 65+/-0.2 ng GH/ml plasma. Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). The specificity for GH release was studied in swine. None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release. In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.

Russianstar "Experiences with Ipamorelin"



Ipamorelin profile.


Firstly just so everyone knows what we are talking about here is a look at one of the best peptides available.

Ipamorelin is a GHRP (growth hormone releasing peptide) receptor-active GH secretagogue, it doesnt significanly effect cortisol or prolactin, so this makes it highly specific for GH release.

Aib-His-D-2-Nal-DPhe-Lys-NH2

It has also been found that 12 weeks of treatment with ipamorelin increased bone mass in young adult female rats in one study that can be found on pubmed.

It is important to remember that Ipamorelin is a ghrelin mimetic, and an analog to ghrelin.
However it doesnt cause the kind of hunger feelings caused by ghrp-6.
Ipamorelin acts with synergy when used during your own GHRH (growth-hormone releasing hormone) pulse or when coadministered with GHRH or a GHRH analog such as Sermorelin or cjc.
The synergy comes about due to both the obvious suppression of somatostatin and the increases in GH release per-somatotrope, while GHRH increases the number of somatotropes that release GH.
Due to the fact that its selective and doesnt really alter cortisol or prolactin levels, this makes Ipamorelin a very exciting peptide, it is as effective as ghrp-6 without the increase in hunger or cortisol or prolactin serum levels, and it has another property unique to Ipamorelin.
A mega-dose of ipamorelin results in a mega-release of GH (up to the entire amount that is actualy present in the pituitary), whereas GHRP-2 and GHRP-6 have limits of approximately 1mcg/kg in humans for their maximal GH release.
I find this very exciting when used directly after training to increase recovery and in the maturation of satelite muscle cells.


Results and experiences.

I used 100mcg 3 times a day, i used it exactly as GHRP-6 in my experiences thread... i used it injected directly in to joints and areas that i have damaged and found over just a 2 week period a massive amount of improvement, in particular in my elbow where i was suffering from a strained ligament.. the pain subsided totaly and full strength returned within 4 weeks.. this was after it hurting on and off for over 3 months. The pain has never returned,

As for its anabolic properties i used 300mcg straight after training to get a much larger pulse in GH, and found recovery improved vastly... over 12 weeks on this protocol i lost about 2 lbs in bodyfat.. but as my BF is very low i think had i been bigger this number would have been considerably higher.
I saw an increase in vascularity.. improved skin texture.. very deep sleep, in fact i was feeling sleepy quite a bith through the day.. minimal water retention and about 3lb gain in mass... sadly i am at my genetic max i feel for size and find it nearly impossible to hold on to anything over my current weight, however 2lb has lasted over 3 months, with the obvious fluctuations in glycogen retention etc... i use an average weight based on 14 readings through the week to get a correct measurement.

If i combined this with something like CJC, wich i hope to do very shortly i feel this could be an incredible combination.. and currently the best peptide combination.. although i still love the effects of ghrp-6, i love the hunger stimulation.
The selective effects of ipamorelin make this a very special peptide..

Russians peptide rating..

10/10


Ipamorelin

 

Ipamorelin or NNC 26-0161, a polypeptide hormone, is a growth hormone secretagogue and ghrelin mimetic and analog developed by Novo Nordisk[3]. Ipamorelin belongs to the most recent generation of GHRPs from the mid 1990s and causes significant release of growth hormone by itself, due both to its suppression of somatostatin (an antagonist to GHRH) and stimulation of release of GH from the anterior pituitary, similar to GHRP-2 and GHRP-6 which are compounds from the same class (growth hormone releasing peptides).[1] The cells that produce and release GH are known as somatotropes.[2] Like GHRP-2 and GHRP-6, ipamorelin does not have ghrelin’s lipogenic properties. Like GHRP-2 and unlike GHRP-6 ipamorelin never induces hunger in mammals. Ipamorelin acts synergistically when applied during a native GHRH (growth-hormone releasing hormone) pulse or when coadministered with GHRH or a GHRH analog such as Sermorelin or GRF 1-29 (growth releasing factor, aminos 1-29).[1] The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH.[1,2]


There is also a secondary effect of neuronal excitation in the hypothalamus caused by ipamorelin, which lasts for approximately 3 hours after application, similar to GHRP-2 and GHRP-6.


Ipamorelin has a unique property among the GHRP class of peptides. That property is known as selectiveness. Raun et al demonstrated the selectiveness of ipamorelin for GH release only in a study:

The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (ECs) = 1.3+/-0.4nmol/l and Emax = 85+/-5% vs 2.2+/-0.3nmol/l and 100%). A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6 (ED50 = 80+/-42nmol/kg and Emax = 1545+/-250ng GH/ml vs 115+/-36nmol/kg and 1167+/-120ng GH/ml). In conscious swine, ipamorelin released GH with an ED50 = 2.3+/-0.03 nmol/kg and an Emax = 65+/-0.2 ng GH/ml plasma. Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). The specificity for GH release was studied in swine. None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release. In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.[3]

Whereas GHRP-6 and GHRP-2 cause a release and increase in cortisol and prolactin levels, ipamorelin only selectively releases GH at any dose. Further, a mega-dose of ipamorelin results in a concomitant mega-release of GH (up to the entire amount present in the pituitary), whereas GHRP-2 and GHRP-6 have limits of approximately 1mcg/kg in humans for their maximal GH release.[4,5]

References:

[1] Bowers CY, Momany F, Reynolds GA. In vitro and in vivo activity of a small synthetic peptide with potent GH releasing activity. 64th Annual Meeting of the Endocrine Society, San Francisco, 1982, p. 205.
[2]Bowers CY, Momany F, Reynolds GA, Sartor O. Multiple receptors mediate GH release. 7th International Congress of Endocrinology, Quebec, Canada, 1984, p. 464.

[3] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.

[4] Brosnan-Cook, M. et al. (1998) Iontophoretic delivery of ipamorelin, a growth hormone secretagogue. Proceedings of 80th Annual Meeting Endocrine Society, New Orleans, USA. Abstract Pp1-186.

[5] Jogarao V S Gobburu; Henrik Agerso; William J Jusko . Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide in Human Volunteers. Lars Ynddal Pharmaceutical Research: Sep 1999; 16, 9; ProQuest Nursing & Allied Health Source p. 1412.

 



HGH & PEPTIDES

 

  
© 2018 Musclefuture.com. All rights reserved.
  
Contact Us 
Shipping & Returns 
Terms & Conditions